Current Combinatorial Therapeutic Aspects: The Future Prospect for Glioblastoma Treatment

This review from @jiitnoida.bsky.social synthesizes current #therapeutic prospects for #Glioblastoma (#GBM) and highlights ongoing advances in treatment strategies, offering valuable insights into the evolving landscape of #GBMResearch. #medsky

Read here: doi.org/10.1007/s115...

Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma | Nature Medicine Glioblastoma (GBM) is an aggressive primary adult brain tumor that rapidly recurs after standard-of-care treatments, including surgery, chemotherapy and radiotherapy. While immune checkpoint inhibitor therapies have transformed outcomes in many tumor types, particularly when used neoadjuvantly or as a first-line treatment, including in melanoma brain metastases, they have shown limited efficacy in patients with resected or recurrent GBM. The lack of efficacy has been attributed to the scarcity of tumor-infiltrating lymphocytes (TILs), an immunosuppressive tumor microenvironment and low tumor mutation burden typical of GBM tumors, plus exclusion of large molecules from the brain parenchyma. We hypothesized that upfront neoadjuvant combination immunotherapy, administered with disease in situ, could induce a stronger immune response than treatment given after resection or after recurrence. Here, we present a case of newly diagnosed IDH-wild-type, MGMT promoter unmethylated GBM, treated wi

Neoadjuvant triplet immune checkpoint blockade shows promise in new GBM: a tough brain tumor. Early yet; could transform brain cancer therapy! #GBMResearch PMID:40016450, Nat Med 2025, @NatureMedicine https://doi.org/10.1038/s41591-025-03512-1 #Medsky #Pharmsky #RNAsky 🧪

Thanks @neuroonc.bsky.social for the opportunity to present our work on GBM Invasion and ECM stiffness!! Very excited to be here and learn from leaders in the field! #SNO2024 @DoctorQMd @DoctorQMDLab @paulaschiappa1 @emilynorton295 @HugoGuerreroLab @tae_hwang @KKLabJHU #NeuroOncology #GBMResearch